Cencora (COR) continues to demonstrate impressive financial performance and earnings growth. With increased stock positions from several financial institutes and having yielded a 193% return on investments made five years ago, the biotech company showed an uptick in strength as share value jumped 3.7% and overall year-to-date gains at 13.2% and 16.6% at different points. However, it was noted that the five-year earnings growth was trailing the year-on-year shareholder returns. Further engagement from investors was evident with the purchase of high volume of call options. Cencora also successfully achieved an upgrade in relative strength rating and earned a 'buy' rating. Meanwhile, Walgreens Boots Alliance has been gradually reducing its stake in Cencora with share sales amounting to billions. A brief decline in the stock was flagged but did not detract from its overall growth trend. Despite missing revenue estimates due to a shortage in weight-loss drugs, and a revised outlook followed by a cyberattack compromising additional data, Cencora has consistently shown resilience. Looking forward, earnings forecasts, Evernorth contract renewal and Cigna change are expected to have a 'minimal' impact on the 2025 earnings per share.
Cencora COR News Analytics from Fri, 03 Nov 2023 07:00:00 GMT to Sat, 19 Oct 2024 14:18:57 GMT -
Rating 9
- Innovation 7
- Information 8
- Rumor 2
